

DAFTAR PUSTAKA

- Asaduzzaman, M., Constantinou, S., Min, H., Gallon, J., Lin, M.-L., Singh, P., Raguz, S., Ali, S., Shousha, S., Coombes, R.C., Lam, E.W.-F., Hu, Y. and Yagüe, E., 2017. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. *Breast Cancer Research and Treatment*, 163(3), pp.461–474.
- Bhullar, K.S., Lagarón, N.O., McGowan, E.M., Parmar, I., Jha, A., Hubbard, B.P. and Rupasinghe, H.P.V., 2018. Kinase-targeted cancer therapies: progress, challenges and future directions. *Molecular Cancer*, 17(1), p.48.
- Birbo, B., Madu, E.E., Madu, C.O., Jain, A. and Lu, Y., 2021. Role of HSP90 in cancer. *International Journal of Molecular Sciences*, 22(19).
- Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A.G., Slaby, O., Ionescu, C. and Berindan-Neagoe, I., 2019. A comprehensive review on MAPK: A promising therapeutic target in cancer. *Cancers*, 11(10).
- Brand, T.M., Iida, M. and Wheeler, D.L., 2011. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. *Cancer Biology & Therapy*, 11(9), pp.777–792.
- Brennan, A., Leech, J.T., Kad, N.M. and Mason, J.M., 2020. Selective antagonism of cJun for cancer therapy. *Journal of Experimental & Clinical Cancer Research*, 39(1), p.184.
- Chang, B.Y., Kim, S.B., Lee, M.K., Park, H. and Kim, S.Y., 2015. Improved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4. *International Journal of Molecular Sciences*, 16(10), pp.24139–24158.
- Chan, E.W.C., Wong, S.K., Tangah, J., Inoue, T. and Chan, H.T., 2020. Phenolic constituents and anticancer properties of Morus alba (white mulberry) leaves. *Journal of integrative medicine*, 18(3), pp.189–195.
- Cho, S.W., Na, W., Choi, M., Kang, S.J., Lee, S.-G. and Choi, C.Y., 2017. Autophagy inhibits cell death induced by the anti-cancer drug morusin. *American journal of cancer research*, 7(3), pp.518–530.
- Chun, R., 2007. Cancer Chemotherapy. In: *Withrow & macewen's small animal clinical oncology*. Elsevier.pp.163–192.
- Dabili, S., Fallah, S., Aein, M., Vatannejad, A., Panahi, G., Fadaei, R., Moradi, N. and Shojaii, A., 2019. Survey of the effect of doxorubicin and flavonoid extract of white Morus alba leaf on apoptosis induction in a-172 GBM cell line. *Archives of physiology and biochemistry*, 125(2), pp.136–141.

- Deepa, M. and Priya, S., 2012. Purification and characterization of a novel anti-proliferative lectin from *Morus alba* L. leaves. *Protein and Peptide Letters*, 19(8), pp.839–845.
- Deepa, M., Sureshkumar, T., Satheeshkumar, P.K. and Priya, S., 2013. Antioxidant rich *Morus alba* leaf extract induces apoptosis in human colon and breast cancer cells by the downregulation of nitric oxide produced by inducible nitric oxide synthase. *Nutrition and Cancer*, 65(2), pp.305–310.
- Di Marco, A., Arcamone, F. and Zunino, F., 1975. Daunomycin (daunorubicin) and adriamycin and structural analogues: biological activity and mechanism of action. In: J.W. Corcoran, F.E. Hahn, J.F. Snell and K.L. Arora, eds. *Mechanism of action of antimicrobial and antitumor agents*. Berlin, Heidelberg: Springer Berlin Heidelberg. pp.101–128.
- Dytho, M.S. and Sutrisna, E.M., 2021. POTENSI JATI BELANDA (*Guazuma ulmifolia*) SEBAGAI TERAPI HERBAL UNTUK KANKER: STUDI LITERATUR.
- Garces de Los Fayos Alonso, I., Liang, H.-C., Turner, S.D., Lager, S., Merkel, O. and Kenner, L., 2018. The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas. *Cancers*, 10(4).
- Giridharan, S. and Srinivasan, M., 2018. Mechanisms of NF- κ B p65 and strategies for therapeutic manipulation. *Journal of inflammation research*, 11, pp.407–419.
- Goel, S., Bergholz, J.S. and Zhao, J.J., 2022. Targeting CDK4 and CDK6 in cancer. *Nature Reviews. Cancer*.
- Guo, C., Liu, S., Wang, J., Sun, M.-Z. and Greenaway, F.T., 2013. ACTB in cancer. *Clinica Chimica Acta*, 417, pp.39–44.
- Hajalsiddig, T.T.H., Osman, A.B.M. and Saeed, A.E.M., 2020. 2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors. *ACS omega*, 5(30), pp.18662–18674.
- Hardianti, B., Umeyama, L., Li, F., Yokoyama, S. and Hayakawa, Y., 2020. Anti-inflammatory compounds moracin O and P from *Morus alba* Linn. (Sohakuhi) target the NF- κ B pathway. *Molecular medicine reports*, 22(6), pp.5385–5391.
- Harrison, C. and Vannucchi, A.M., 2012. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. *Therapeutic advances in hematology*, 3(6), pp.341–354.

- Hemmings, B.A. and Restuccia, D.F., 2012. PI3K-PKB/Akt pathway. *Cold Spring Harbor Perspectives in Biology*, 4(9), p.a011189.
- Hermawan, A., Ikawati, M., Jenie, R.I., Khumaira, A., Putri, H., Nurhayati, I.P., Angraini, S.M. and Muflikhasari, H.A., 2021. Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, 29(1), pp.12–26.
- Hinz, N. and Jücker, M., 2019. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. *Cell Communication and Signaling*, 17(1), p.154.
- Howard, M.D., 2005. Thiotepe. In: *Encyclopedia of Toxicology*. Elsevier. pp.175–177.
- Hurtado, D.X., Castellanos, F.A., Coy-Barrera, E. and Tello, E., 2020. Prostaglandins Isolated from the Octocoral *Plexaura homomalla*: In Silico and In Vitro Studies Against Different Enzymes of Cancer. *Marine Drugs*, 18(3).
- Kampan, N.C., Madondo, M.T., McNally, O.M., Quinn, M. and Plebanski, M., 2015. Paclitaxel and its evolving role in the management of ovarian cancer. *BioMed research international*, 2015, p.413076.
- Kang, S., Kim, E.-O., Kim, S.-H., Lee, J.-H., Ahn, K.S., Yun, M. and Lee, S.-G., 2017. Morusin induces apoptosis by regulating expression of Bax and Survivin in human breast cancer cells. *Oncology letters*, 13(6), pp.4558–4562.
- Kufareva, I. and Abagyan, R., 2008. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. *Journal of Medicinal Chemistry*, 51(24), pp.7921–7932.
- Kujawska, M., Ewertowska, M., Adamska, T., Ignatowicz, E., Flaczyk, E., Przeor, M., Kurpik, M. and Liebert, J.J., 2016. Protective Effect of *Morus alba* Leaf Extract on N-Nitrosodiethylamine-induced Hepatocarcinogenesis in Rats. *In Vivo*, 30(6), pp.807–812.
- Kwon, D.H., Cheon, J.M., Choi, E.-O., Jeong, J.W., Lee, K.W., Kim, K.Y., Kim, S.G., Kim, S., Hong, S.H., Park, C., Hwang, H.-J. and Choi, Y.H., 2016. The Immunomodulatory Activity of *Mori folium*, the Leaf of *Morus alba* L., in RAW 264.7 Macrophages In Vitro. *Journal of cancer prevention*, 21(3), pp.144–151.
- Labrie, F., 1993. Mechanism of action and pure antiandrogenic properties of flutamide. *Cancer*, 72(12 Suppl), pp.3816–3827.

- Lallo, S., Hardianti, B., Umar, H., Trisurani, W., Wahyuni, A. and Latifah, M., 2020. Aktivitas Anti Inflamasi dan Penyembuhan Luka dari Ekstrak Kulit Batang Murbei (*Morus alba* L.). *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy)*, 6(1), pp.26–36.
- Lee, H., Jeong, A.J. and Ye, S.-K., 2019. Highlighted STAT3 as a potential drug target for cancer therapy. *BMB Reports*, 52(7), pp.415–423.
- Lee, S.R., Park, J.Y., Yu, J.S., Lee, S.O., Ryu, J.-Y., Choi, S.-Z., Kang, K.S., Yamabe, N. and Kim, K.H., 2016. Odisolane, a Novel Oxolane Derivative, and Antiangiogenic Constituents from the Fruits of Mulberry (*Morus alba* L.). *Journal of Agricultural and Food Chemistry*, 64(19), pp.3804–3809.
- Lim, S.-L., Park, S.-Y., Kang, S., Park, D., Kim, S.-H., Um, J.-Y., Jang, H.-J., Lee, J.-H., Jeong, C.-H., Jang, J.-H., Ahn, K.S. and Lee, S.-G., 2015. Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. *American journal of cancer research*, 5(1), pp.289–299.
- Liu, L.F., Desai, S.D., Li, T.K., Mao, Y., Sun, M. and Sim, S.P., 2000. Mechanism of action of camptothecin. *Annals of the New York Academy of Sciences*, 922, pp.1–10.
- Li, Z.-H., Yu, D., Huang, N.-N., Wu, J.-K., Du, X.-W. and Wang, X.-J., 2021. Immunoregulatory mechanism studies of ginseng leaves on lung cancer based on network pharmacology and molecular docking. *Scientific Reports*, 11(1), p.18201.
- Madden, S.K., de Araujo, A.D., Gerhardt, M., Fairlie, D.P. and Mason, J.M., 2021. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. *Molecular Cancer*, 20(1), p.3.
- Masoud, G.N. and Li, W., 2015. HIF-1 α pathway: role, regulation and intervention for cancer therapy. *Acta pharmaceutica Sinica. B*, 5(5), pp.378–389.
- Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G.N. and Ueno, N.T., 2012. Role of epidermal growth factor receptor in breast cancer. *Breast Cancer Research and Treatment*, 136(2), pp.331–345.
- Mena, A.C., Pulido, E.G. and Guillén-Ponce, C., 2010. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. *Anti-Cancer Drugs*, 21 Suppl 1, pp.S3-11.
- Montecucco, A., Zanetta, F. and Biamonti, G., 2015. Molecular mechanisms of etoposide. *EXCLI journal*, 14, pp.95–108.
- Mortlock, A., Foote, K., Kettle, J. and Aquila, B., 2014. Kinase inhibitors in cancer. In: *Reference module in chemistry, molecular sciences and chemical engineering*. Elsevier.

- Muhammad, N., Bhattacharya, S., Steele, R., Phillips, N. and Ray, R.B., 2017. Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*, 23(12), pp.3120–3128.
- Noor, F., Rehman, A., Ashfaq, U.A., Saleem, M.H., Okla, M.K., Al-Hashimi, A., AbdElgawad, H. and Aslam, S., 2022. Integrating Network Pharmacology and Molecular Docking Approaches to Decipher the Multi-Target Pharmacological Mechanism of *Abrus precatorius* L. Acting on Diabetes. *Pharmaceuticals (Basel, Switzerland)*, 15(4).
- Olsson, M. and Zhivotovsky, B., 2011. Caspases and cancer. *Cell Death and Differentiation*, 18(9), pp.1441–1449.
- Opdam, F.L., Guchelaar, H.-J., Beijnen, J.H. and Schellens, J.H.M., 2012. Lapatinib for advanced or metastatic breast cancer. *The Oncologist*, 17(4), pp.536–542.
- Ozaki, T. and Nakagawara, A., 2011. Role of p53 in cell death and human cancers. *Cancers*, 3(1), pp.994–1013.
- Park, H.-J., Chi, G.-Y., Choi, Y.-H. and Park, S.-H., 2020. The root bark of *Morus alba* L. regulates tumor-associated macrophages by blocking recruitment and M2 polarization of macrophages. *Phytotherapy Research*, 34(12), pp.3333–3344.
- Park, H.-J. and Park, S.-H., 2020. Induction of cytoprotective autophagy by morusin via AMP-activated protein kinase activation in human non-small cell lung cancer cells. *Nutrition research and practice*, 14(5), pp.478–489.
- Patil, R., Das, S., Stanley, A., Yadav, L., Sudhakar, A. and Varma, A.K., 2010. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. *Plos One*, 5(8), p.e12029.
- Rong, B. and Yang, S., 2018. Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review). *International Journal of Oncology*, 52(2), pp.321–336.
- Saranya, J., Shilpa, G., Raghu, K.G. and Priya, S., 2017. *Morus alba* Leaf Lectin (MLL) Sensitizes MCF-7 Cells to Anoikis by Inhibiting Fibronectin Mediated Integrin-FAK Signaling through Ras and Activation of P38 MAPK. *Frontiers in pharmacology*, 8, p.34.
- Schettino, C., Bareschino, M.A., Ricci, V. and Ciardiello, F., 2008. Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. *Expert review of respiratory medicine*, 2(2), pp.167–178.

- Scholar, E., 2007. Nilutamide. In: *xPharm: The Comprehensive Pharmacology Reference*. Elsevier.pp.1–5.
- Segovia-Mendoza, M., González-González, M.E., Barrera, D., Díaz, L. and García-Becerra, R., 2015. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. *American journal of cancer research*, 5(9), pp.2531–2561.
- Sharif Siam, M.K., Sarker, A. and Sayeem, M.M.S., 2021. In silico drug design and molecular docking studies targeting Akt1 (RAC-alpha serine/threonine-protein kinase) and Akt2 (RAC-beta serine/threonine-protein kinase) proteins and investigation of CYP (cytochrome P450) inhibitors against MAOB (monoamine oxidase B) for OSCC (oral squamous cell carcinoma) treatment. *Journal of Biomolecular Structure & Dynamics*, 39(17), pp.6467–6479.
- Sharma, S., Carlson, S., Gregory-Flores, A., Hinojo-Perez, A., Olson, A. and Thippeswamy, T., 2021. Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy. *Neurobiology of Disease*, 156, p.105410.
- Shirai, Y., Chow, C.C.T., Kambe, G., Suwa, T., Kobayashi, M., Takahashi, I., Harada, H. and Nam, J.-M., 2021. An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor. *Cancers*, 13(11).
- Sinha, N. and Smith-Gill, S.J., 2002. Electrostatics in protein binding and function. *Current Protein & Peptide Science*, 3(6), pp.601–614.
- Sprangers, B., Pirenne, J., Mathieu, C. and Waer, M., 2014. Other forms of immunosuppression. In: *Kidney transplantation—principles and practice*. Elsevier.pp.320–338.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71(3), pp.209–249.
- Sun, Y. and Yang, J., 2019. A bioinformatics investigation into the pharmacological mechanisms of the effect of Fufang Danshen on pain based on methodologies of network pharmacology. *Scientific Reports*, 9(1), p.5913.
- Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P. and Zhu, H.-P., 2017. Risk factors and preventions of breast cancer. *International Journal of Biological Sciences*, 13(11), pp.1387–1397.

- Tahara, M., Nomura, S. and Hashimoto, M., 2003. [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor]. *Nippon Yakurigaku Zasshi. Folia Pharmacologica Japonica*, 122(4), pp.345–354.
- Thorn, C.F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T.E. and Altman, R.B., 2011. Doxorubicin pathways: pharmacodynamics and adverse effects. *Pharmacogenetics and Genomics*, 21(7), pp.440–446.
- Tsang, R.Y., Sadeghi, S. and Finn, R.S., 2011. Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside. *Clinical Medicine Insights: Therapeutics*, 3, p.CMT.S3783.
- Utami, F.S. and Muhartati, M., 2020. Kader sadar kanker payudara. *Jurnal Ilmiah Akuntansi dan Keuangan*, 1(1), pp.19–22.
- Wang, J., Liu, X., Zheng, H., Liu, Q., Zhang, H., Wang, X., Shen, T., Wang, S. and Ren, D., 2020. Morusin induces apoptosis and autophagy via JNK, ERK and PI3K/Akt signaling in human lung carcinoma cells. *Chemico-Biological Interactions*, 331, p.109279.
- Wang, T., Fan, L., Feng, S., Ding, X., An, X., Chen, J., Wang, M., Zhai, X. and Li, Y., 2022. Network pharmacology of iridoid glycosides from *Eucommia ulmoides* Oliver against osteoporosis. *Scientific Reports*, 12(1), p.7430.
- Wang, X. and Lin, Y., 2008. Tumor necrosis factor and cancer, buddies or foes? *Acta Pharmacologica Sinica*, 29(11), pp.1275–1288.
- Wan, Y., Xu, L., Liu, Z., Yang, M., Jiang, X., Zhang, Q. and Huang, J., 2019. Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms. *BMC complementary and alternative medicine*, 19(1), p.158.
- Weichert, W., Boehm, M., Gekeler, V., Bahra, M., Langrehr, J., Neuhaus, P., Denkert, C., Imre, G., Weller, C., Hofmann, H.P., Niesporek, S., Jacob, J., Dietel, M., Scheidereit, C. and Kristiansen, G., 2007. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. *British Journal of Cancer*, 97(4), pp.523–530.
- Wells, B.G., DiPiro, J.T., Schwinghammer, T.L. and DiPiro, C.V., 2017. *Pharmacotherapy Handbook, Tenth Edition*.
- Wilson, A.C., Meethal, S.V., Bowen, R.L. and Atwood, C.S., 2007. Leuprolide acetate: a drug of diverse clinical applications. *Expert Opinion on Investigational Drugs*, 16(11), pp.1851–1863.

- Yu, J.S., Lee, D., Lee, S.R., Lee, J.W., Choi, C.-I., Jang, T.S., Kang, K.S. and Kim, K.H., 2018. Chemical characterization of cytotoxic indole acetic acid derivative from mulberry fruit (*Morus alba* L.) against human cervical cancer. *Bioorganic Chemistry*, 76, pp.28–36.
- Zhang, M.-M., Wang, D., Lu, F., Zhao, R., Ye, X., He, L., Ai, L. and Wu, C.-J., 2021. Identification of the active substances and mechanisms of ginger for the treatment of colon cancer based on network pharmacology and molecular docking. *BioData mining*, 14(1), p.1.
- Zhang, S. and Yu, D., 2012. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. *Trends in Pharmacological Sciences*, 33(3), pp.122–128.
- Zhang, X., Shen, T., Zhou, X., Tang, X., Gao, R., Xu, L., Wang, L., Zhou, Z., Lin, J. and Hu, Y., 2020. Network pharmacology based virtual screening of active constituents of *Prunella vulgaris* L. and the molecular mechanism against breast cancer. *Scientific Reports*, 10(1), p.15730.

